HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)

THE LANCET ONCOLOGY (TLO)

Chernobyl, ionising radiation exposure, and cancer risk
The first review in this months TLO reviews the epidemiological evidence linking cancer incidence as a result of the 1986 Chernobyl nuclear explosion in the Ukraine. Most studies have focused on malignant diseases in children, specifically thyroid cancer and leukaemia. Authors of the review argue that there is good evidence to suggest that rates of thyroid cancer in children from the countries that were formally part of the Soviet Union have risen as a consequence of the Chernobyl accident. The findings for childhood leukaemia, they comment, are less conclusive. Among adult populations, there is no strong evidence to suggest that risk of thyroid cancer, leukaemia, or other malignant disease has increased as a result of the Chernobyl accident.

Hormone-replacement therapy (HRT) and breast cancer
HRT has been available for many years, but the important question of its place in development and progression of breast cancer remains controversial. This review summarises current clinical data, which suggest that short-term HRT use does not increase breast-cancer risk, although a small increase in risk is associated with long-term (more than 10 years) HRT use. The review highlights the need for prospective controlled trials in healthy women as well as those at higher risk of breast cancer or with a personal history of the disease.

A case for geriatric oncology
The increase in cancer incidence with increasing age is becoming more obvious and more important as the average age of the population increases. This review assesses the biological and clinical interactions of cancer and ageing and discusses the skills and knowledge necessary for caring for older patients.

A culture of mistrust
This months Leading Edge editorial examines the issues surrounding diet and cancer, especially media reports that often
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
1-May-2002


Page: 1 2 3

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Oncology (TLO)
5. The Lancet Infectious Diseases (TLID)
6. The Lancet Neurology November press release
7. Lancet readers to join WHO election debate
8. The Lancet Oncology press release
9. The Lancet Neurology October press release
10. The Lancet neurology press release
11. The Lancet Neurology press release

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Lancet Oncology TLO and The Lancet Infectious Diseases TLID

(Date:10/31/2014)... 31, 2014 At the start of ... narrowly escaping carbon monoxide poisoning in their homes. Now, ... away, one family-owned, Missouri-based heating and cooling company is ... sure families start the home heating season with the ... , Beginning Nov. 1, 2014, E and Q ...
(Date:10/31/2014)... UT (PRWEB) October 31, 2014 ... new Activz Silver line offering natural silver ... wipes. For over a century, silver has been used ... in Activz Silver products is the most advanced version ... has a unique chemical structure that supports the existing ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... News) -- Obesity increases the risk of certain types ... two new U.S. studies show. One study of ... obese increased the risk for estrogen receptor-negative and progesterone ... this for a long time for white women, but ... study author Esther John, a senior research scientist at ...
(Date:10/31/2014)... insomnia is a major contributor to deaths caused by ... results underscore the importance of the "Sleep Well, Be ... , Results show that the risk of unintentional fatal ... of insomnia symptoms present. People with all three symptoms ... from a fatal injury than those with no insomnia ...
Breaking Medicine News(10 mins):Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)... announces the list of stocks featured in the Analyst Blog. Every ... events impacting stocks and the financial markets. Stocks recently featured in ... Report ), Celgene (Nasdaq: CELG - Free Report ... ), Market Vectors Biotech ETF (AMEX: BBH - ... XBI - Free Report ). Today, Zacks is ...
(Date:10/31/2014)... , October 31, 2014 Multigate Medical ... patents of B. Braun Melsungen AG (B. Braun) by selling ... safety IV catheters manufactured by Poly Medicure Ltd (Polymed). The ... proceeding number VID 463 of 2013 can be ... detailed judgment, Multigate was found to have infringed claim 1 ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2
Cached News: